News | October 10, 2024
India’s emergence as a hub for affordable medicines is commendable: Dr. Jitendra Singh
We now rank 3rd in pharmaceutical production by volume and 14th by value
We now rank 3rd in pharmaceutical production by volume and 14th by value
Dr Reddy’s has partnered with MSN Laboratories Private Limited on the product, with Dr Reddy’s holding exclusive US marketing rights while MSN leads development and manufacturing
Knowledge paper highlights biosimilars, biologics, AI-driven drug discovery and regulatory excellence as key growth drivers for the next phase of India's pharma expansion
The union minister spoke at the 2nd Pharma Summit & Awards 2026 organised by ASSOCHAM in New Delhi
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
Expands Davaindia network to 2,579 stores
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Subscribe To Our Newsletter & Stay Updated
